Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Will The Ischemic Heart Disease (IHD) Drugs Market Valuation Change Between Now And 2029?

In recent times, the market size of drugs for ischemic heart disease (IHD) has been expanding steadily. The market, which stood at $6.36 billion in 2024, is expected to reach $6.65 billion by 2025, marking a compound annual growth rate (CAGR) of 4.5%. This growth during the historical period is a consequence of several factors such as a surge in worldwide cases of ischemic heart disease, enhancements in awareness and diagnostic measures, alterations in lifestyle and dietary habits, government protocol to boost cardiovascular health, partnerships for conducting clinical trials, and insurance coverage along with reimbursement policies.

The market for ischemic heart disease (IHD) medication is projected to experience consistent growth in the coming years, expected to reach “$7.7 billion by 2029 with a compound annual growth rate (CAGR) of 3.7%. This growth in the predicted period can be credited to factors such as the trends of an aging population, personalized medical practices, emphasis on cardiovascular prevention, as well as global health policies and initiatives, along with global research alliances. The projection period will likely witness a shift towards precision medicine practices, a heightened emphasis on novel anti-atherogenic agents, advancements in therapies that lower lipid levels, integration of anti-inflammatory medications, and the creation of antithrombotic and antiplatelet drugs.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

Which Key Factors Are Fueling Growth In The Ischemic Heart Disease (IHD) Drugs Market?

The escalating rates of obesity and diabetes are anticipated to fuel the expansion of the ischemic heart disease (IHD) drugs market in the future. Diabetes, a chronic metabolic condition, results in elevated blood sugar levels, whereas obesity, marked by excessive body fat, can pose adverse effects on health. Drugs for ischemic heart disease are commonly prescribed to individuals with obesity and diabetes to manage cardiovascular risk elements like hypertension and dyslipidemia, thus reducing the risk of ischemic heart disease. For example, as per the World Obesity Federation’s data in 2022, a United Kingdom-based organization aimed at international efforts to cut down, avoid, and treat obesity, by 2030, one billion individuals worldwide, including one in every five women and one in every seven men, are projected to have obesity. According to the UK’s National Health Service in June 2024, the NHS detected an additional 549,000 individuals in England who could potentially develop type 2 diabetes in 2023. This brought the total count of people diagnosed with non-diabetic hyperglycemia, or prediabetes, and registered with a GP to 3,615,330. This is a considerable increase from 3,065,825 in 2022, showing almost a 20% hike. Therefore, the increasing rates of obesity and diabetes underpin the growth of the ischemic heart disease (IHD) drugs market.

What Are The Main Segment Classifications In The Ischemic Heart Disease (IHD) Drugs Market?

The ischemic heart disease (ihd) drugs market covered in this report is segmented –

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors

2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers

4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril

5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan

6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine

7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

How Are Industry Trends Steering The Expansion Of The Ischemic Heart Disease (IHD) Drugs Market?

Major firms in the ischemic heart disease (IHD) drugs market are concentrating on the creation of novel myosin inhibitors to strengthen their market position. A cardiac myosin inhibitor is a type of medication that reduces the activity of myosin in the heart muscle, thus reducing contraction stress. This is useful for conditions such as hypertrophic cardiomyopathy (HCM), a condition where excessive thickening of heart muscle affects its functioning. In April 2022, for example, Bristol Myers Squibb, a pharmaceutical company based in the US, introduced Camzyos (mavacamten). This is the first cardiac myosin inhibitor to be approved for treating adults with symptomatic New York Heart Association Class II-III obstructive hypertrophic cardiomyopathy (HCM), aimed to enhance functional capacity and alleviate symptoms. The medication acts as an allosteric and reversible inhibitor selective for cardiac myosin, reducing hypercontractility, left ventricular hypertrophy, and enhancing cardiac filling pressures. Consequently, this contributes to a decrease in dynamic left ventricular outflow tract (LVOT) obstruction.

Who Are The Major Stakeholders Operating In The Ischemic Heart Disease (IHD) Drugs Market?

Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

What Are The Emerging Regional Trends Driving The Ischemic Heart Disease (IHD) Drugs Market?

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model